Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia

Launched by UNIVERSITY OF NAMIBIA · Aug 19, 2021

Keywords

ClinConnect Summary

This clinical trial, called the H3TB study, is focused on understanding and controlling drug-resistant tuberculosis (DR-TB) in Namibia. With a significant number of new cases each year, the study aims to investigate where DR-TB is spreading most quickly and identify groups of people who may be at higher risk. Researchers will collect various types of information, including health data and genetic information from the bacteria causing the disease, to help uncover the patterns of transmission. The ultimate goal is to develop better strategies for finding and treating DR-TB cases and to inform health policies in Namibia and beyond.

To participate in the study, individuals diagnosed with drug-resistant TB from specific regions in Namibia are eligible, along with their household members, hospital visitors, and community members living near hotspots of transmission. Participants will be involved in data collection, which may include answering questions about their health and providing samples for testing. This study not only aims to strengthen the diagnosis and control of DR-TB but also seeks to allocate resources effectively to areas most in need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All cases diagnosed with drug-resistant TB in Namibia, in three regions of Khomas, Otjozondjupa and Ohangwena will be included for the first outcome. For the second outcome, all household members of DR-TB cases will be included; all hospital visitors to DR-TB cases will be included and community members at transmission hotspots will be included.
• Exclusion Criteria:
• • Anyone who does not give consent to participate.